Arginase-1 deficiency.

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder affecting the urea cycle.
• Mutations in the ARG1 gene lead to loss of enzyme function, causing hyperargininemia and neurological impairment.
• Clinical presentation differs from other urea cycle disorders, featuring spastic paraparesis and intellectual decline.

Purpose of the Study:

• To review current understanding of ARG1 deficiency etiology and pathophysiology.
• To highlight new developments using ARG1 knockout mouse models.
• To discuss potential therapeutic strategies and future research directions.

Main Methods:

• Review of clinical case reports and historical therapeutic strategies.
• Utilizing ARG1 global and inducible knockout mouse models to study pathophysiology.
• Gene transfer studies in mouse models.

Main Results:

• Mouse models provide insights into ARG1 deficiency pathophysiology.
• Gene transfer studies suggest potential therapeutic avenues.
• Mouse models exhibit a more severe phenotype than human patients, requiring cautious interpretation.

Conclusions:

• ARG1 deficiency presents a unique clinical and biochemical profile.
• Mouse models are valuable tools for understanding ARG1 deficiency, but limitations exist.
• Further research is needed to develop effective treatments for ARG1 deficiency.